A phase 1b study of famitinib plus docetaxel as 2nd line setting in patients with metastatic non-squamous non-small cell lung cancer and EGFR wild type.

作者:Caicun, Zhou; Shengxiang, Ren; ChunXia, Su; Fengying, Wu; Xiaoxia, Chen; Fei, Zhou; Jing, Zhao; Tao, Jiang; Jing, Wang; Qing, Yang; Yuanyuan, Yu
来源:Journal of Clinical Oncology, 2016, 34(15_suppl): e20603-e20603.
DOI:10.1200/jco.2016.34.15_suppl.e20603

全文